Vaccination Covid

The risk of rare heart inflammation after getting an mRNA Covid vaccine were notably higher among young men, researchers found, but still much lower than ...

Ryan, who is also a clinical professor at the University of California San Diego, said the finding with mRNA vaccines should be used to “propel the field forward” and “spur the development of safer vaccines or precision vaccination practices.” Covid-19 carries a more significant risk of heart issues alongside a litany of other problems. Heart inflammation, especially among young men, was an unexpected adverse event linked to mRNA shots.

At the time of FDA approval for any vaccine, it is impossible to know whether it causes rare, unexpected serious adverse reactions.

The only way to know if these are adverse reactions caused by the vaccine or not is to focus less on VAERS reports and instead examine the VSD and BEST data. Whatever the truth is, we need to convincingly determine whether there is a problem or not and make that evidence public. CDC and FDA have the data, systems and knowledge to answer the concerns. If an adverse reaction happens in only one in 10,000 people, and we see one or two such adverse reactions in the clinical trial, that is not enough to determine if the vaccine caused the reaction or if it occurred because of chance alone. The pharmaceutical companies do not have the data needed to answer vaccine safety questions properly, and whatever side-effect information reported to them must be forwarded to VAERS. We know there is a small risk of myocarditis, but we do not yet know enough about other potential heart problems, nor about the long-term consequences of vaccine-induced myocarditis. Administered jointly by the CDC and the FDA, VAERS is a passive reporting system where anyone can report a plausible or suspected adverse vaccine to the CDC/FDA, including physicians, nurses, patients, families, and friends. Covid mortality is exceptionally low for children and young adults, so for them it is unclear whether the limited benefit of vaccination outweighs the still unknown safety profile of the vaccine. To accurately determine whether the vaccine was responsible for those events, we need to know precisely how many people were vaccinated, and we need to receive all their health events as well as health events from an unvaccinated comparison group. Since clinical trials are too small to tell us whether the vaccine causes rare but serious adverse reactions, it is necessary to do post-market safety surveillance after the FDA has already approved the product. Over the last two decades, I worked closely with the CDC and the FDA to help design the systems used to track vaccine safety after FDA approval. At the time of FDA approval for any vaccine, it is impossible to know whether it causes rare, unexpected serious adverse reactions.

The pandemic stole focus from other, deadlier diseases, including HIV/AIDS in the developing world.

Increasing access to HIV treatments could actually do more than a global vaccination campaign to halt the spread of Covid in low-income countries. It’s in the “national interest to vaccinate the world and protect against any possible future variant,” White House Covid czar Jeff Zients said last week. Now the world is awash in vaccines, and demand has petered out in low-income countries. Covid ranks low on the list of public-health threats in Africa. A little more than 250,000 Africans have died from Covid. That’s not even close to the number of Africans who died in 2019 from non-Covid lower respiratory infections, diarrheal diseases such as cholera, HIV/AIDS, malaria and tuberculosis. While the U.S. has donated hundreds of millions of mRNA vaccines to low-income countries, these must be stored at frigid temperatures and usually administered within hours once vials are opened. But other infectious diseases that are much deadlier than Covid in low-income countries have taken a back seat during the pandemic.

Among COVID-19 vaccinations, we examined the effect of the type of vaccine (mRNA or non-mRNA), sex, age, and dose on the incidence of myopericarditis. This ...

- In the midst of the devastating COVID-19 pandemic, rapid development of highly effective vaccines was enthusiastically welcomed. - 82.Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults. It is also important to interpret the risks and benefits in the context of the background incidence of myopericarditis across subpopulations—ie, the risk of myopericarditis will depend on the prevailing prevalence of COVID-19 locally and at the time of vaccination. In people who received a COVID-19 vaccine, our results showed that myopericarditis was nearly four times as common in those receiving an mRNA vaccine than a non-mRNA vaccine and in those receiving their second dose of vaccine compared with a first or third dose. Additionally, given current robust vaccine surveillance systems and the fact that COVID-19 vaccines have received a much higher degree of scrutiny than previous vaccines, the possibility of relative under-reporting of adverse events following non-COVID-19 vaccinations cannot be excluded, despite mass vaccination of more than 6 billion people in the past year. We also found that young men have a higher incidence of myopericarditis than others receiving mRNA COVID-19 vaccinations. Vaccine doses, n Definitions of pericarditis, myocarditis, and myopericarditis in individual studies or databases are summarised in the 38 We clustered the pooled estimates around each unique study identifier to derive the robust-variance estimates for SE. In addition, we evaluated differences in the incidences of myocarditis and pericarditis between COVID-19 and non-COVID-19 vaccines. We also did a sensitivity analysis excluding any database and preprint data and studies with high risks of bias (JBI score <7) to assess the impact of intra-study risk of bias on the reporting of myopericarditis. The screening of studies, data collection, and risk of bias assessment were done independently in duplicate by RRL, FLT, and KR; disagreements were resolved by consensus. Although a number of mechanisms have been suggested, the actual mechanism for the pathogenesis of post-vaccine myopericarditis has not been established.

Cette augmentation des hospitalisations et du nombre d'absents chez le personnel soignant a d'ailleurs laissé entrevoir de nouveaux délestages dans le réseau de ...

Les autorités ont rapporté qu’en une semaine, la hausse des hospitalisations s’est élevée à plus de 28 %. Les Québécois âgés de 60 ans et plus peuvent commencer ce lundi à prendre rendez-vous pour une quatrième dose d’un vaccin contre la COVID-19. La quatrième dose contre la COVID-19 disponible pour les 60 ans et plus

Research finds risk of myopericarditis after Covid jab is low and similar to that after flu vaccine.

However, even among young men, rates of myopericarditis after a Covid jab were comparable to other vaccinations. This is similar to incidence after a flu vaccine and after other types of vaccination. “Millions of people around the world have had a Covid vaccine, virtually all without complication,” he said.